A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.
Patrick F SmithJanakan KrishnarajahPhilip A NunnRon J HillDane KarrD TamMohammad MasjedizadehJens O FunkSteve G GourlayPublished in: British journal of clinical pharmacology (2017)
PRN1008 was safe and well-tolerated following oral administration, and achieved high, sustained levels of BTK occupancy in peripheral blood mononuclear cells.